๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Compound trial record
Trackers Drugs Trial finder
Compound · clinical trials

Corticosteroids

Also listed in trial records as Infliximab, 5-ASA, 5-Aminosalicylic acid
Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 22 trials in our China, USA, UK, India and Ireland registers that name Corticosteroids as an intervention. Synced 24 Sep 2026
22Trials tracked
11Recruiting now
17Lead sponsors
5Country registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 โ€” Top 14 finalist
Compiled from ClinicalTrials.gov registry records ยท Last verified ยท Editorial standards

Corticosteroids is named as a drug or biological intervention in 22 clinical trials in our China, USA, UK, India and Ireland trial registers, 11 of which are recruiting. Lead sponsors include Incyte Corporation (2), Sanofi (2) and Bristol-Myers Squibb (2). Registered phases: Phase 3, Phase 2, Phase 4, Not applicable, Phase 2/3 and Observational. Conditions studied include Chronic Graft-versus-host-disease; Dermatitis Atopic; Ulcerative Colitis.

Corticosteroids also has an approved-drug profile on this site (FDA label data): Remicade (Infliximab) →
01

Clinical trials of Corticosteroids

22 trials
NCT IDStudyPhaseStatusLead sponsorRegister
NCT04999228 Top Down Versus Step up in Pediatric Ulcerative Colitis (ClinicalTrials.gov ↗)
Ulcerative Colitis, Infliximab, Children
Phase 4 Recruiting Children's Hospital of Fudan University China
NCT05043870 Combined Immunosuppression for Pediatric Crohn's Disease (ClinicalTrials.gov ↗)
Crohn Disease, Infliximab, Immunosuppression
Phase 4 Recruiting Children's Hospital of Fudan University China
NCT05514015 Clinical Study of Rituximab Combined With Corticosteroids or Rituximab Monotherapy in the Treatment of Primary Membranous Nephropathy (ClinicalTrials.gov ↗)
Primary Membranous Nephropathy
Phase 4 Recruiting First Affiliated Hospital, Sun Yat-Sen University China
NCT07550673 Upadacitinib Versus Infliximab as Second-Line Treatment for Acute Severe Ulcerative Colitis๏ผˆUPRISE๏ผ‰ (ClinicalTrials.gov ↗)
Acute Severe Ulcerative Colitis
Phase 4 Recruiting Xijing Hospital of Digestive Diseases China
NCT04381936 Randomised Evaluation of COVID-19 Therapy (ClinicalTrials.gov ↗)
Pneumonia
Phase 3 Recruiting University of Oxford India
NCT04877288 A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications (ClinicalTrials.gov ↗)
Renal Allograft Recipients
Phase 3 Recruiting Bristol-Myers Squibb UK, USA
NCT06585774 A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
Chronic Graft-versus-host-disease
Phase 3 Recruiting Incyte Corporation Ireland, UK, USA
NCT03804931 Fecal Microbiota Transplantation for Ulcerative Colitis (ClinicalTrials.gov ↗)
Ulcerative Colitis, Fecal Microbiota Transplantation
Phase 2/3 Recruiting Guangzhou First People's Hospital China
NCT07340723 Novel First-line Therapies for Grade II Acute GVHD(Graft-versus-host Disease ) (ClinicalTrials.gov ↗)
GVHD,Acute, Stem Cell Transplant Complications
Phase 2 Recruiting Daihong Liu China
NCT07680764 A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Locally Advanced Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer (NSCLC)
Phase 2 Recruiting Bristol-Myers Squibb UK, USA, China
NCT07694674 Comparison of the Efficacy of Different Biologic Agents in Preventing Postoperative Endoscopic Recurrence of Crohn's Disease (ClinicalTrials.gov ↗)
Inflamatory Bowel Disease, Crohn Disease (CD)
Observational Recruiting Shanghai 10th People's Hospital China
NCT07297069 Combination Therapy With Infliximab and Tofacitinib for Acute Severe Ulcerative Colitis - CINTO Trial (ClinicalTrials.gov ↗)
Acute Severe Ulcerative Colitis
Phase 2 Not yet open Asian Institute of Gastroenterology, India India
NCT07424040 The Efficacy and Safety of Infliximab Combination With Azathioprine in Crohn's Disease in Children (ClinicalTrials.gov ↗)
Crohn's Diseases, Crohn's Disease in Pediatric Patient
Not applicable Not yet open The Children's Hospital of Zhejiang University School of Medicine China
NCT03568318 A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (ClinicalTrials.gov ↗)
Atopic Dermatitis
Phase 3 Active, closed AbbVie Ireland, UK, USA, China
NCT03596645 A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (ClinicalTrials.gov ↗)
Colitis, Ulcerative
Phase 3 Active, closed Janssen Research & Development, LLC USA
NCT05345171 Clinical Study of DTX301 AAV-Mediated Gene Transfer for Ornithine Transcarbamylase (OTC) Deficiency (ClinicalTrials.gov ↗)
OTC Deficiency
Phase 3 Active, closed Ultragenyx Pharmaceutical Inc USA
NCT05653349 Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP) (ClinicalTrials.gov ↗)
Primary Immune Thrombocytopenia (ITP)
Phase 3 Active, closed Novartis Pharmaceuticals UK, USA, India, China
NCT06241118 A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor (ClinicalTrials.gov ↗)
Dermatitis Atopic
Phase 3 Active, closed Sanofi UK, USA, China
NCT05492578 Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials (ClinicalTrials.gov ↗)
Dermatitis Atopic
Phase 2/3 Active, closed Sanofi UK, USA, India, China
NCT06388564 A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease (ClinicalTrials.gov ↗)
Chronic Graft-versus-host-disease
Phase 2 Active, closed Incyte Corporation UK, USA
NCT07149441 Efficacy and Mechanism of FMT in the Treatment of Inflammatory Bowel Disease: an Open-label Randomized Controlled Study (ClinicalTrials.gov ↗)
Inflammatory Bowel Disease (Crohn&Amp;#39;s Disease and Ulcerative Colitis), Fecal Microbiota Transplantation
Not applicable Active, closed Shanghai 10th People's Hospital China
NCT07176754 TNF-ฮฑ Antagonists Mitigate Systemic Inflammatory Response After Cardiac Arrest. (ClinicalTrials.gov ↗)
Cardiac Arrest (CA), Post Cardiac Arrest Syndrome
Not applicable Active, closed Peking University Third Hospital China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

02

Conditions studied

28 conditions
Condition (as registered)Trials
Chronic Graft-versus-host-disease2
Dermatitis Atopic2
Ulcerative Colitis2
Infliximab2
Acute Severe Ulcerative Colitis2
Fecal Microbiota Transplantation2
Atopic Dermatitis1
Renal Allograft Recipients1
Primary Immune Thrombocytopenia (ITP)1
OTC Deficiency1
Pneumonia1
GVHD,Acute1
Stem Cell Transplant Complications1
Primary Membranous Nephropathy1
Children1
Locally Advanced Non-Small Cell Lung Cancer (NSCLC)1
Metastatic Non-Small Cell Lung Cancer (NSCLC)1
Colitis, Ulcerative1
Crohn's Diseases1
Crohn's Disease in Pediatric Patient1
Cardiac Arrest (CA)1
Post Cardiac Arrest Syndrome1
Crohn Disease1
Immunosuppression1
Children, Only1
Inflammatory Bowel Disease (Crohn&Amp;#39;s Disease and Ulcerative Colitis)1
Inflamatory Bowel Disease1
Crohn Disease (CD)1
03

Sponsors

lead sponsor per trial
Lead sponsorTrials
Incyte Corporation2
Sanofi2
Bristol-Myers Squibb2
Children's Hospital of Fudan University2
Shanghai 10th People's Hospital2
AbbVie1
Novartis Pharmaceuticals1
Ultragenyx Pharmaceutical Inc1
University of Oxford1
Daihong Liu1
First Affiliated Hospital, Sun Yat-Sen University1
Janssen Research & Development, LLC1
Asian Institute of Gastroenterology, India1
The Children's Hospital of Zhejiang University School of Medicine1
Peking University Third Hospital1
Xijing Hospital of Digestive Diseases1
Guangzhou First People's Hospital1
04

Trials by country register

A trial with sites in more than one country appears in each of those registers.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records โ€” it is not written from memory, and nothing here describes how Corticosteroids works or whether it is effective. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Corticosteroids (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician โ€” our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us โ€” we correct promptly and log it.